Endre søk
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
The prostaglandin E1 analog misoprostol reduces symptoms and microvascular arteriovenous shunting in erythromelalgia-a double-blind, crossover, placebo-compared study.
Rikshospitalet University Hospital.
Linköpings universitet.
Karlstads universitet.ORCID-id: 0000-0002-3356-9952
Ulleval University Hospital.
2004 (engelsk)Inngår i: Journal of Investigative Dermatology, ISSN 0022-202X, E-ISSN 1523-1747, Vol. 122, nr 3, s. 587-93Artikkel i tidsskrift (Fagfellevurdert) Published
Abstract [en]

Based on previous experience with parenteral prostanoids, we studied the effect of misoprostol treatment, an orally administered prostaglandin E1 analog, in patients with erythromelalgia. Treatment with placebo was followed by treatment with misoprostol (0.4-0.8 mg per d), both for 6 wk. The patients (n=21) and a study nurse who administered the trial were blinded. The endpoints were change in pain and need for cooling and global assessment of the treatment. Following central body heat provocation, global skin perfusion, capillary morphology, and change in pain were also recorded before and after each treatment period. Results were compared with data from healthy control subjects (n=11) that did not undergo treatment. Clinical safety and tolerability evaluation included physical examinations, clinical laboratory tests, and monitoring of adverse events. All clinical outcome measures were significantly better after treatment with misoprostol (p<0.01) as compared with placebo treatment and after a 3- mo follow-up without treatment. The heat-induced increase in global perfusion after misoprostol treatment was similar to the control group and significantly lower when compared with baseline (p<0.01) and placebo treatment (p<0.05), respectively. This study demonstrates that misoprostol is clinically superior to placebo in patients with erythromelalgia. The results of the perfusion studies may imply that the mechanism of action of the beneficial effect of misoprostol is reduced microvascular arteriovenous shunting in affected skin.

sted, utgiver, år, opplag, sider
2004. Vol. 122, nr 3, s. 587-93
HSV kategori
Forskningsprogram
Biomedicinsk lab. Vetenskap
Identifikatorer
URN: urn:nbn:se:kau:diva-3195DOI: 10.1111/j.0022-202X.2004.22339.xPubMedID: 15086539OAI: oai:DiVA.org:kau-3195DiVA, id: diva2:128368
Tilgjengelig fra: 2008-12-16 Laget: 2008-12-16 Sist oppdatert: 2018-01-13bibliografisk kontrollert

Open Access i DiVA

fulltekst(350 kB)699 nedlastinger
Filinformasjon
Fil FULLTEXT01.pdfFilstørrelse 350 kBChecksum SHA-512
ff9d8760ba48a752437a811b346a34cba38acd7cc2da578da8b01b64ea0b88681f39eb94eda865b33532794979ab4eb86ede07dff5f95f1ddf99aff80277ffce
Type fulltextMimetype application/pdf

Andre lenker

Forlagets fulltekstPubMedhttp://www.nature.com/jid/journal/v122/n3/full/5602219a.html

Personposter BETA

Asker, Claes L

Søk i DiVA

Av forfatter/redaktør
Asker, Claes L
Av organisasjonen
I samme tidsskrift
Journal of Investigative Dermatology

Søk utenfor DiVA

GoogleGoogle Scholar
Totalt: 699 nedlastinger
Antall nedlastinger er summen av alle nedlastinger av alle fulltekster. Det kan for eksempel være tidligere versjoner som er ikke lenger tilgjengelige

doi
pubmed
urn-nbn

Altmetric

doi
pubmed
urn-nbn
Totalt: 356 treff
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf